logo
Plus   Neg
Share
Email

ConocoPhillips Q2 Adj. Profit Misses Estimates - Quick Facts

ConocoPhillips (COP) on Tuesday reported that its earnings for the second quarter were $1.6 billion or $1.40 per share, compared with $1.6 billion or $1.39 per share in the year-ago period.

Special items for the latest quarter were primarily driven by a financial tax benefit related to the previously announced U.K. disposition, settlement of certain tax disputes, and amounts recognized from the PDVSA International Chamber of Commerce or ICC settlement.

Excluding special items, adjusted earnings for the quarter were $1.1 billion or $1.01 per share, compared with adjusted earnings of $1.3 billion or $1.09 per share in the year-ago period.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $1.03 per share for the quarter. Analysts' estimates typically exclude special items.

Production excluding Libya for the second quarter of 2019 was 1,290 thousand barrels of oil equivalent per day or MBOED, an increase of 79 MBOED compared with the same period a year ago.

During the quarter, ConocoPhillips increased its 2019 planned share repurchases to $3.5 billion.

Looking ahead, ConocoPhillips forecast third-quarter 2019 production to be 1,290 to 1,330 MBOED, reflecting planned turnarounds in Alaska, Europe and Asia Pacific.

The company projects full-year production in a range of 1,310 to 1,340 MBOED. The guidance excludes Libya.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions. McDonald's is adding renewable energy to the grid, as part of its efforts to address climate change. The fast-food giant said it signed two long-term, large-scale virtual power purchase agreements or VPPAs to buy renewable energy generated by wind and solar power. Under the agreements, McDonald's will buy a combined 380MW in renewable energy.
Follow RTT
>